Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022;100(12):666-673.
doi: 10.1159/000526140. Epub 2022 Aug 31.

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study

Mariam Jafri  1 , Hartmut Kristeleit  2 , Vivek Misra  3 , Mark Baxter  4 , Samreen Ahmed  5 , Apurna Jegannathen  6 , Ankit Jain  7 , David Maskell  8 , Urmila Barthakur  9 , Gwenllian Edwards  10 , Harriet S Walter  11 , Richard Walshaw  12 , Madeha Khan  13 , Annabel Borley  14 , Daniel Rea  1   15
Affiliations
Multicenter Study

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study

Mariam Jafri et al. Oncology. 2022.

Abstract

Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.

Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).

Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).

Discussion/conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

Keywords: Eribulin; Metastatic breast cancer; Observation study; Older adults; Real-world data; Second-line treatment.

PubMed Disclaimer

Conflict of interest statement

Dr. Mariam Jafri reports receiving personal fees from Eisai during the conduct of the study; personal fees from Roche, Pfizer, and Lilly, outside the submitted work. Dr. Samreen Ahmed reports receiving consultancy and advisory fees from Eisai. Dr. Annabel Borley reports personal fees from a commercial sponsor, outside the submitted work (i.e., an honorarium for participating in the Steering Committee for First Thoughts Educational Meeting 2018). Dr. Hartmut Kristeleit reports personal fees from Eisai during the conduct of the study; personal fees from Novartis and Roche; personal fees and other from Pfizer; and other from Daiichi-Sankyo, outside the submitted work. Dr. Vivek Misra reports personal fees from Eisai UK, outside the submitted work. Dr. Daniel Rea reports nonfinancial support from Eisai and Novartis; personal fees from Roche, Novartis, Pfizer, and Lily; grants from Roche, Biotheranostics, and RNA Diagnostics; and personal fees from Daiichi-Sankyo, outside the submitted work. Dr. Urmila Barthakur, Dr. Mark Baxter, Dr. Gwenllian Edwards, Dr. Ankit Jain, Dr. Apurna Jegannathen, Dr. Madeha Khan, Dr. David Maskell, Dr. Richard Walshaw, and Dr. Harriet S. Walter have nothing to disclose.

Figures

Fig. 1
Fig. 1
Age distribution in the ITT population (a), the ER status (b), and the Her2 status (c) of the eribulin-treated patient cohort. ER, estrogen receptor; ITT, intent-to-treat; Her2, human epidermal growth factor receptor 2.
Fig. 2
Fig. 2
Sites of metastases (a) and the number of prior lines of chemotherapy (b) among the patient cohort. Some patients may have had more than 1 site of metastasis.
Fig. 3
Fig. 3
Kaplan-Meier estimate of OS for patients with triple-negative MBC compared with patients with Her2/ER-positive MBC. “Her2/ER-positive” were those patients who were ER-positive and/or Her2-positive. ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival.
Fig. 4
Fig. 4
Kaplan-Meier estimate of OS for patients with or without brain metastases. OS, overall survival.
Fig. 5
Fig. 5
Kaplan-Meier estimate of OS for patients who had received >2 lines of chemotherapy and for patients who had received ≤2 lines of chemotherapy before eribulin treatment (ITT population). ITT, intent-to-treat; OS, overall survival.
Fig. 6
Fig. 6
Kaplan-Meier estimate of OS for patients ≥65 years old compared with patients <65 years old (ITT population). ITT, intent-to-treat; OS, overall survival.
See this image and copyright information in PMC

References

    1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10((Suppl 3)):20–9. - PubMed
    1. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23((Suppl 7)):vii11–9. - PubMed
    1. Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer a systematic literature review. Breast Cancer Res. 2019;21((1)):143. - PMC - PubMed
    1. Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. Cancers. 2020;12((4)):916. - PMC - PubMed
    1. Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, et al. Change in survival in metastatic breast cancer with treatment advances meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2((4)):pky062. - PMC - PubMed

Publication types